{"id": "article-31467_0", "title": "Zileuton -- Continuing Education Activity", "content": "Zileuton, a 5-lipoxygenase inhibitor, is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 and older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids\u00a0for chronic asthma, it is not effective for managing acute asthma attacks.", "contents": "Zileuton -- Continuing Education Activity. Zileuton, a 5-lipoxygenase inhibitor, is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 and older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids\u00a0for chronic asthma, it is not effective for managing acute asthma attacks."}
{"id": "article-31467_1", "title": "Zileuton -- Continuing Education Activity", "content": "Zileuton is also used off-label in patients with aspirin-induced asthma. The application of the drug extends to aspirin-induced asthma, with research supporting its efficacy in chronic obstructive pulmonary disease and dermatological conditions such as acne, pruritic manifestations in Sj\u00f6gren-Larsson syndrome, and atopic dermatitis. This activity delves into the complexities of clinical toxicity, drug interactions, pharmacokinetics, and the importance of vigilant monitoring while administering zileuton to patients. This activity equips the interprofessional healthcare team with the necessary skills to manage diverse clinical scenarios and\u00a0improve\u00a0patient care in the context of respiratory and dermatological conditions\u00a0using zileuton effectively.", "contents": "Zileuton -- Continuing Education Activity. Zileuton is also used off-label in patients with aspirin-induced asthma. The application of the drug extends to aspirin-induced asthma, with research supporting its efficacy in chronic obstructive pulmonary disease and dermatological conditions such as acne, pruritic manifestations in Sj\u00f6gren-Larsson syndrome, and atopic dermatitis. This activity delves into the complexities of clinical toxicity, drug interactions, pharmacokinetics, and the importance of vigilant monitoring while administering zileuton to patients. This activity equips the interprofessional healthcare team with the necessary skills to manage diverse clinical scenarios and\u00a0improve\u00a0patient care in the context of respiratory and dermatological conditions\u00a0using zileuton effectively."}
{"id": "article-31467_2", "title": "Zileuton -- Continuing Education Activity", "content": "Objectives: Identify appropriate candidates for zileuton therapy based on their age (12 and older) and a diagnosis of chronic asthma. Implement vigilant monitoring protocols for patients receiving zileuton, considering clinical toxicity, drug interactions, and pharmacokinetics. Select optimal combinations of zileuton with other medications for patients with chronic myeloid leukemia or aspirin-exacerbated respiratory disease. Collaborate with the interprofessional healthcare team to coordinate comprehensive patient care, integrating zileuton appropriately into treatment plans. Access free multiple choice questions on this topic.", "contents": "Zileuton -- Continuing Education Activity. Objectives: Identify appropriate candidates for zileuton therapy based on their age (12 and older) and a diagnosis of chronic asthma. Implement vigilant monitoring protocols for patients receiving zileuton, considering clinical toxicity, drug interactions, and pharmacokinetics. Select optimal combinations of zileuton with other medications for patients with chronic myeloid leukemia or aspirin-exacerbated respiratory disease. Collaborate with the interprofessional healthcare team to coordinate comprehensive patient care, integrating zileuton appropriately into treatment plans. Access free multiple choice questions on this topic."}
{"id": "article-31467_3", "title": "Zileuton -- Indications", "content": "Zileuton is a 5-lipoxygenase inhibitor approved by the United States Food and Drug Administration (FDA) for the prophylaxis and treatment of chronic asthma in patients aged 12 and older. [1]", "contents": "Zileuton -- Indications. Zileuton is a 5-lipoxygenase inhibitor approved by the United States Food and Drug Administration (FDA) for the prophylaxis and treatment of chronic asthma in patients aged 12 and older. [1]"}
{"id": "article-31467_4", "title": "Zileuton -- Indications -- FDA-Approved Indication", "content": "Zileuton is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 or older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids\u00a0for chronic asthma, it is not effective for managing acute asthma attacks.", "contents": "Zileuton -- Indications -- FDA-Approved Indication. Zileuton is a primary intervention for the prophylaxis and treatment of chronic asthma in patients aged 12 or older. Although zileuton is frequently administered in conjunction with inhaled corticosteroids\u00a0for chronic asthma, it is not effective for managing acute asthma attacks."}
{"id": "article-31467_5", "title": "Zileuton -- Indications -- Off-Label Uses", "content": "Zileuton is also used off-label in patients with aspirin-induced asthma. [2] Research supports the effectiveness of zileuton in treating patients with chronic obstructive pulmonary disease, upper airway inflammatory conditions, and dermatological conditions such as acne, pruritus in Sj\u00f6gren-Larsson syndrome, and atopic dermatitis. [3]", "contents": "Zileuton -- Indications -- Off-Label Uses. Zileuton is also used off-label in patients with aspirin-induced asthma. [2] Research supports the effectiveness of zileuton in treating patients with chronic obstructive pulmonary disease, upper airway inflammatory conditions, and dermatological conditions such as acne, pruritus in Sj\u00f6gren-Larsson syndrome, and atopic dermatitis. [3]"}
{"id": "article-31467_6", "title": "Zileuton -- Indications -- Off-Label Uses", "content": "Studies have demonstrated that individuals with exercise-induced asthma can derive benefits from the drug when administered 1 hour before exercise. In addition, zileuton\u00a0has shown efficacy in inhibiting chronic myeloid leukemia, whether combined with imatinib or as a standalone treatment. [4] A recent study has also indicated that zileuton\u00a0may decrease the necessity for sinus surgeries in aspirin-exacerbated respiratory disease. [5] In addition, a topical formulation of zileuton\u00a0is currently under investigation for treating atopic dermatitis . [6] Clinicians are advised to conduct a thorough risk-benefit analysis before considering using zileuton for off-label indications.", "contents": "Zileuton -- Indications -- Off-Label Uses. Studies have demonstrated that individuals with exercise-induced asthma can derive benefits from the drug when administered 1 hour before exercise. In addition, zileuton\u00a0has shown efficacy in inhibiting chronic myeloid leukemia, whether combined with imatinib or as a standalone treatment. [4] A recent study has also indicated that zileuton\u00a0may decrease the necessity for sinus surgeries in aspirin-exacerbated respiratory disease. [5] In addition, a topical formulation of zileuton\u00a0is currently under investigation for treating atopic dermatitis . [6] Clinicians are advised to conduct a thorough risk-benefit analysis before considering using zileuton for off-label indications."}
{"id": "article-31467_7", "title": "Zileuton -- Mechanism of Action", "content": "Currently, 2\u00a0primary approaches to leukotriene inhibition are recognized. One approach is antagonistic blockage of cys-LT1 receptors from cysteinyl leukotrienes on bronchial smooth muscle cells, which is the mechanism of action for montelukast and zafirlukast. [7] [8] [9] The second approach is the inhibition of 5-lipoxygenase. The enzyme 5-lipoxygenase is necessary for the biosynthesis of leukotrienes. Zileuton is a 5-lipoxygenase inhibitor that inhibits the formation of leukotrienes B4, C4, D4, and E4. Limiting these leukotrienes helps reduce inflammation, edema, mucus secretion, and bronchoconstriction in the airways. This action reduces leukocyte adhesion, smooth muscle contraction, capillary permeability, and the migration and aggregation of neutrophils and eosinophils. Consequently, a reduction in asthma exacerbations is evidenced by improving asthma symptoms. [3]", "contents": "Zileuton -- Mechanism of Action. Currently, 2\u00a0primary approaches to leukotriene inhibition are recognized. One approach is antagonistic blockage of cys-LT1 receptors from cysteinyl leukotrienes on bronchial smooth muscle cells, which is the mechanism of action for montelukast and zafirlukast. [7] [8] [9] The second approach is the inhibition of 5-lipoxygenase. The enzyme 5-lipoxygenase is necessary for the biosynthesis of leukotrienes. Zileuton is a 5-lipoxygenase inhibitor that inhibits the formation of leukotrienes B4, C4, D4, and E4. Limiting these leukotrienes helps reduce inflammation, edema, mucus secretion, and bronchoconstriction in the airways. This action reduces leukocyte adhesion, smooth muscle contraction, capillary permeability, and the migration and aggregation of neutrophils and eosinophils. Consequently, a reduction in asthma exacerbations is evidenced by improving asthma symptoms. [3]"}
{"id": "article-31467_8", "title": "Zileuton -- Mechanism of Action", "content": "Recent research suggests that\u00a0the phosphatidylinositide 3-kinase (PI3K) pathway is a major determinant of clinical response to Zileuton\u00a0patients with asthma. Patients showing poor response to zileuton have increased activation of PIK3CA, resulting in increased leukotriene B4\u00a0production\u00a0and resistance to Zileuton therapy. Higher concentrations of leukotriene-B4\u00a0can bind to GPCR, leading to increased PIK3CA signaling and proliferation of pro-inflammatory responses mediated by leukotriene activity. In contrast, patients with\u00a0positive responses would have limited leukotriene B4\u00a0production following Zileuton treatment. [10]", "contents": "Zileuton -- Mechanism of Action. Recent research suggests that\u00a0the phosphatidylinositide 3-kinase (PI3K) pathway is a major determinant of clinical response to Zileuton\u00a0patients with asthma. Patients showing poor response to zileuton have increased activation of PIK3CA, resulting in increased leukotriene B4\u00a0production\u00a0and resistance to Zileuton therapy. Higher concentrations of leukotriene-B4\u00a0can bind to GPCR, leading to increased PIK3CA signaling and proliferation of pro-inflammatory responses mediated by leukotriene activity. In contrast, patients with\u00a0positive responses would have limited leukotriene B4\u00a0production following Zileuton treatment. [10]"}
{"id": "article-31467_9", "title": "Zileuton -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: According to the manufacturer's labeling, zileuton is rapidly absorbed upon oral administration, and peak plasma concentration is attained in approximately 1.7 hours.", "contents": "Zileuton -- Mechanism of Action -- Pharmacokinetics. Absorption: According to the manufacturer's labeling, zileuton is rapidly absorbed upon oral administration, and peak plasma concentration is attained in approximately 1.7 hours."}
{"id": "article-31467_10", "title": "Zileuton -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Zileuton has an apparent volume of distribution of approximately 1.2 L/kg. Zileuton has high plasma protein binding (93%). It is primarily bound to albumin; a small proportion is bound to \u03b1-1-acid glycoprotein.", "contents": "Zileuton -- Mechanism of Action -- Pharmacokinetics. Distribution: Zileuton has an apparent volume of distribution of approximately 1.2 L/kg. Zileuton has high plasma protein binding (93%). It is primarily bound to albumin; a small proportion is bound to \u03b1-1-acid glycoprotein."}
{"id": "article-31467_11", "title": "Zileuton -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Zileuton is primarily metabolized in the liver by the cytochrome P450 system, including CYP1A2, CYP2C9, and CYP3A4. Zileuton's metabolites include\u00a02 glucuronide conjugates (significant metabolites) and an N -dehydroxylated metabolite. Pharmacodynamic activity is primarily due to the parent drug. Elimination: Zileuton and its metabolites are primarily excreted in the urine (94.5%). The mean terminal half-life of zileuton\u00a0is 2.5 hours. [11]", "contents": "Zileuton -- Mechanism of Action -- Pharmacokinetics. Metabolism: Zileuton is primarily metabolized in the liver by the cytochrome P450 system, including CYP1A2, CYP2C9, and CYP3A4. Zileuton's metabolites include\u00a02 glucuronide conjugates (significant metabolites) and an N -dehydroxylated metabolite. Pharmacodynamic activity is primarily due to the parent drug. Elimination: Zileuton and its metabolites are primarily excreted in the urine (94.5%). The mean terminal half-life of zileuton\u00a0is 2.5 hours. [11]"}
{"id": "article-31467_12", "title": "Zileuton -- Administration -- Available Dosage Forms and Strengths", "content": "Zileuton is only available in a tablet formulation. The tablets are single-strength, 600 mg white, oval, and film-coated. Zileuton should be stored at room temperature 20 \u00b0C to 25 \u00b0C (68 \u00b0F to 77 \u00b0F). [12]", "contents": "Zileuton -- Administration -- Available Dosage Forms and Strengths. Zileuton is only available in a tablet formulation. The tablets are single-strength, 600 mg white, oval, and film-coated. Zileuton should be stored at room temperature 20 \u00b0C to 25 \u00b0C (68 \u00b0F to 77 \u00b0F). [12]"}
{"id": "article-31467_13", "title": "Zileuton -- Administration -- Adult Dosage", "content": "Administer\u00a02 (600 mg) extended-release tablets twice daily. Administer immediate-release (IR) tablets of 600 mg\u00a04 times daily. [13] Use within\u00a01 hour of morning and evening meals.\u00a0Zileuton can\u00a0be used in conjunction with inhaled corticosteroids. These tablets should not be crushed, split in half, or chewed. Patients should not use this drug for acute asthma attacks. In addition, patients should not take a double dose if they miss a scheduled drug dose.\u00a0Patients are advised not to change the dosage of any other anti-asthma medication unless told by a\u00a0clinician. Zileuton is not the preferred medication in GINA (Global Initiative for Asthma) guidelines. However, a\u00a0study suggests that Zileuton response varies across asthmatics, with\u00a0low response rates associated with those with severe asthma and obesity.\u00a0Consequently, Zileuton and leukotriene receptor antagonists (like Montelukast) could be considered for non-severe asthma. [14]", "contents": "Zileuton -- Administration -- Adult Dosage. Administer\u00a02 (600 mg) extended-release tablets twice daily. Administer immediate-release (IR) tablets of 600 mg\u00a04 times daily. [13] Use within\u00a01 hour of morning and evening meals.\u00a0Zileuton can\u00a0be used in conjunction with inhaled corticosteroids. These tablets should not be crushed, split in half, or chewed. Patients should not use this drug for acute asthma attacks. In addition, patients should not take a double dose if they miss a scheduled drug dose.\u00a0Patients are advised not to change the dosage of any other anti-asthma medication unless told by a\u00a0clinician. Zileuton is not the preferred medication in GINA (Global Initiative for Asthma) guidelines. However, a\u00a0study suggests that Zileuton response varies across asthmatics, with\u00a0low response rates associated with those with severe asthma and obesity.\u00a0Consequently, Zileuton and leukotriene receptor antagonists (like Montelukast) could be considered for non-severe asthma. [14]"}
{"id": "article-31467_14", "title": "Zileuton -- Administration -- Specific Patient Populations", "content": "Renal impairment: Dose adjustment in patients with renal\u00a0impairment or hemodialysis is not\u00a0required.", "contents": "Zileuton -- Administration -- Specific Patient Populations. Renal impairment: Dose adjustment in patients with renal\u00a0impairment or hemodialysis is not\u00a0required."}
{"id": "article-31467_15", "title": "Zileuton -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: Zileuton is contraindicated in patients with active liver disease or constant ALT elevations \u22653 upper limits of normal. Hepatic injury due to zileuton has been self-limited, but the possibility of severe injury and hepatic failure must be evaluated, especially if the medication is not stopped. [13]", "contents": "Zileuton -- Administration -- Specific Patient Populations. Hepatic impairment: Zileuton is contraindicated in patients with active liver disease or constant ALT elevations \u22653 upper limits of normal. Hepatic injury due to zileuton has been self-limited, but the possibility of severe injury and hepatic failure must be evaluated, especially if the medication is not stopped. [13]"}
{"id": "article-31467_16", "title": "Zileuton -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Severe asthma exacerbations, particularly during the first trimester of pregnancy, are\u00a0associated with an increased\u00a0risk of congenital malformations.\u00a0According to GINA guidelines, pregnant patients should be suggested that poorly controlled asthma and exacerbations expose their\u00a0infants to a much greater risk than\u00a0pharmacological treatments. Zileuton is a former FDA pregnancy category C drug. Zileuton\u00a0should be used during pregnancy only after carefully considering the risk-benefit analysis. Other\u00a0agents are preferred as controller and reliever medications. [15] [16] [17]", "contents": "Zileuton -- Administration -- Specific Patient Populations. Pregnancy considerations: Severe asthma exacerbations, particularly during the first trimester of pregnancy, are\u00a0associated with an increased\u00a0risk of congenital malformations.\u00a0According to GINA guidelines, pregnant patients should be suggested that poorly controlled asthma and exacerbations expose their\u00a0infants to a much greater risk than\u00a0pharmacological treatments. Zileuton is a former FDA pregnancy category C drug. Zileuton\u00a0should be used during pregnancy only after carefully considering the risk-benefit analysis. Other\u00a0agents are preferred as controller and reliever medications. [15] [16] [17]"}
{"id": "article-31467_17", "title": "Zileuton -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: No\u00a0medical\u00a0information exists on using zileuton\u00a0during breastfeeding; however, the manufacturer's data indicate that the\u00a0concentration of zileuton in maternal milk is low. No published experience with zileuton\u00a0during breastfeeding is evidenced, so accordingly, an alternate drug\u00a0should be used, particularly while nursing a newborn or preterm infant. [18] Pediatric patients: Zileuton is not FDA-approved for asthma management in pediatric patients aged 12 or younger. Older\u00a0patients: Patients aged 65\u00a0or older taking Zileuton\u00a0IR are at a higher risk of developing elevated ALT levels. [19]", "contents": "Zileuton -- Administration -- Specific Patient Populations. Breastfeeding considerations: No\u00a0medical\u00a0information exists on using zileuton\u00a0during breastfeeding; however, the manufacturer's data indicate that the\u00a0concentration of zileuton in maternal milk is low. No published experience with zileuton\u00a0during breastfeeding is evidenced, so accordingly, an alternate drug\u00a0should be used, particularly while nursing a newborn or preterm infant. [18] Pediatric patients: Zileuton is not FDA-approved for asthma management in pediatric patients aged 12 or younger. Older\u00a0patients: Patients aged 65\u00a0or older taking Zileuton\u00a0IR are at a higher risk of developing elevated ALT levels. [19]"}
{"id": "article-31467_18", "title": "Zileuton -- Adverse Effects", "content": "Serum alanine aminotransferase (ALT) concentration must be obtained from the patient before the Zileuton treatment, as hepatotoxicity can occur. The pattern of liver injury is hepatocellular, and ALT is the most sensitive liver enzyme for liver injury with Zileuton treatments. [13] Symptoms include jaundice, right upper abdominal pain, edema, or pruritus. If ALT concentration is normal, concentration must be monitored once a month for the first\u00a03 months and then every\u00a03 months for the year. [13] After that, they require periodic monitoring\u00a0when receiving long-term treatment. Discontinuation of the drug can cause a resolution of toxicity within 21 days. Patients with a history of liver disease or excessive alcohol\u00a0consumption should use zileuton cautiously.\u00a0Rechallenge of Zileuton should be avoided as it leads to the recurrence of hepatotoxicity. [18] [20] [21]", "contents": "Zileuton -- Adverse Effects. Serum alanine aminotransferase (ALT) concentration must be obtained from the patient before the Zileuton treatment, as hepatotoxicity can occur. The pattern of liver injury is hepatocellular, and ALT is the most sensitive liver enzyme for liver injury with Zileuton treatments. [13] Symptoms include jaundice, right upper abdominal pain, edema, or pruritus. If ALT concentration is normal, concentration must be monitored once a month for the first\u00a03 months and then every\u00a03 months for the year. [13] After that, they require periodic monitoring\u00a0when receiving long-term treatment. Discontinuation of the drug can cause a resolution of toxicity within 21 days. Patients with a history of liver disease or excessive alcohol\u00a0consumption should use zileuton cautiously.\u00a0Rechallenge of Zileuton should be avoided as it leads to the recurrence of hepatotoxicity. [18] [20] [21]"}
{"id": "article-31467_19", "title": "Zileuton -- Adverse Effects", "content": "Patients undergoing long-term therapy (eg, taking zileuton\u00a0for more than\u00a06 months) may experience frequent headaches, upper respiratory tract infections, diarrhea, or myalgia. However, these symptoms are similar to placebo treatment in many cases, eg, headache: 25% for zileuton and 24% for placebo. In one study, dyspepsia was the most statistically significant\u00a0adverse\u00a0effect compared to the placebo group. [1] Other reported adverse events include sinusitis, nausea, headache, abdominal pain, or pharyngolaryngeal pain. Zileuton can infrequently cause a decrease in white blood cell count.\u00a0In most\u00a0cases, the white blood cell count returned to normal or baseline without changing the Zileuton treatment. [22]", "contents": "Zileuton -- Adverse Effects. Patients undergoing long-term therapy (eg, taking zileuton\u00a0for more than\u00a06 months) may experience frequent headaches, upper respiratory tract infections, diarrhea, or myalgia. However, these symptoms are similar to placebo treatment in many cases, eg, headache: 25% for zileuton and 24% for placebo. In one study, dyspepsia was the most statistically significant\u00a0adverse\u00a0effect compared to the placebo group. [1] Other reported adverse events include sinusitis, nausea, headache, abdominal pain, or pharyngolaryngeal pain. Zileuton can infrequently cause a decrease in white blood cell count.\u00a0In most\u00a0cases, the white blood cell count returned to normal or baseline without changing the Zileuton treatment. [22]"}
{"id": "article-31467_20", "title": "Zileuton -- Adverse Effects -- Drug-Drug Interactions", "content": "Concurrent use of Loxapine should be avoided due to the risk of severe bronchospasm. [23] CYP1A2 inhibitors like zileuton may\u00a0increase the serum concentration of Tizanidine and lead to\u00a0adverse reactions such as bradycardia and hypotension. Avoid concurrent administration. [24] Monitor liver function tests (LFT) and plasma concentrations of Theophylline, Warfarin, and Propranolol, as zileuton\u00a0can increase serum concentrations of these medications when taken simultaneously. [13] Studies have shown a 15% decrease in Warfarin clearance, significantly increasing prothrombin times. Therefore, the recommendation is to monitor prothrombin times if the patient takes Warfarin with Zileuton. [25]", "contents": "Zileuton -- Adverse Effects -- Drug-Drug Interactions. Concurrent use of Loxapine should be avoided due to the risk of severe bronchospasm. [23] CYP1A2 inhibitors like zileuton may\u00a0increase the serum concentration of Tizanidine and lead to\u00a0adverse reactions such as bradycardia and hypotension. Avoid concurrent administration. [24] Monitor liver function tests (LFT) and plasma concentrations of Theophylline, Warfarin, and Propranolol, as zileuton\u00a0can increase serum concentrations of these medications when taken simultaneously. [13] Studies have shown a 15% decrease in Warfarin clearance, significantly increasing prothrombin times. Therefore, the recommendation is to monitor prothrombin times if the patient takes Warfarin with Zileuton. [25]"}
{"id": "article-31467_21", "title": "Zileuton -- Adverse Effects", "content": "Research has shown that patients taking zileuton\u00a0IR tablets and Propranolol experienced an increase in serum\u00a0level concentration within\u00a05 days, leading to bradycardia and the risk for hypotension. Therefore, patients taking Propranolol or other beta-blocking agents must be monitored or have their beta-blocker dose reduced to prevent complications. [26] Concurrent administration of theophylline\u00a0and zileuton\u00a0leads to a reduction in Theophylline clearance within\u00a05 days. Clinicians should monitor the plasma concentrations of theophylline in patients and reduce the dosage accordingly.\u00a0Adjust the maintenance dose if the patient is already on zileuton. [27]", "contents": "Zileuton -- Adverse Effects. Research has shown that patients taking zileuton\u00a0IR tablets and Propranolol experienced an increase in serum\u00a0level concentration within\u00a05 days, leading to bradycardia and the risk for hypotension. Therefore, patients taking Propranolol or other beta-blocking agents must be monitored or have their beta-blocker dose reduced to prevent complications. [26] Concurrent administration of theophylline\u00a0and zileuton\u00a0leads to a reduction in Theophylline clearance within\u00a05 days. Clinicians should monitor the plasma concentrations of theophylline in patients and reduce the dosage accordingly.\u00a0Adjust the maintenance dose if the patient is already on zileuton. [27]"}
{"id": "article-31467_22", "title": "Zileuton -- Contraindications -- Box Warnings", "content": "Patients with active liver disease or a history of hypersensitivity to zileuton\u00a0or excipients\u00a0should not take the medication. When using zileuton, patients with ALT elevations more than\u00a03 times the normal upper limit should avoid taking zileuton and consider a different therapy course. [28] [29]", "contents": "Zileuton -- Contraindications -- Box Warnings. Patients with active liver disease or a history of hypersensitivity to zileuton\u00a0or excipients\u00a0should not take the medication. When using zileuton, patients with ALT elevations more than\u00a03 times the normal upper limit should avoid taking zileuton and consider a different therapy course. [28] [29]"}
{"id": "article-31467_23", "title": "Zileuton -- Contraindications -- Warning and Precautions", "content": "Patients taking zileuton may experience sleep disorders or changes in behavior. If neuropsychiatric events occur, patients should contact their clinician. [30] No contraindications exist for use in pregnant patients. However, patients should not use zileuton unless the benefit to the mother justifies the risk to the fetus. [31] Clinicians should avoid prescribing zileuton to patients under 12 as its safety and effectiveness in the age group have not been established. Concerns in this group are primarily due to the risk of hepatotoxicity. Female patients aged over 65 must use zileuton cautiously as they are more susceptible to hepatotoxicity and liver injury. [19]", "contents": "Zileuton -- Contraindications -- Warning and Precautions. Patients taking zileuton may experience sleep disorders or changes in behavior. If neuropsychiatric events occur, patients should contact their clinician. [30] No contraindications exist for use in pregnant patients. However, patients should not use zileuton unless the benefit to the mother justifies the risk to the fetus. [31] Clinicians should avoid prescribing zileuton to patients under 12 as its safety and effectiveness in the age group have not been established. Concerns in this group are primarily due to the risk of hepatotoxicity. Female patients aged over 65 must use zileuton cautiously as they are more susceptible to hepatotoxicity and liver injury. [19]"}
{"id": "article-31467_24", "title": "Zileuton -- Monitoring", "content": "Monitor liver function tests and plasma concentrations of theophylline, warfarin, and propranolol, as zileuton can increase serum concentrations of these medications when taken simultaneously. [13] Monitor for neuropsychiatric adverse drug reactions such as sleep disorders and behavior changes. Monitor pulmonary function tests (typically reversible obstructive pattern) in patients with asthma. [32] National Institute for Clinical Excellence guidelines\u00a0suggest\u00a0spirometry for monitoring asthma at each\u00a0clinic visit or at least after 3 or 6 months from the commencement of\u00a0treatment and afterward every 1 to 2 years. [32] Monitor estimated peak expiratory flow rate; measurements can be variable according to age, height, and race. [33] [34] Repeated peak flow measurement is simple to execute in clinical settings. [35]", "contents": "Zileuton -- Monitoring. Monitor liver function tests and plasma concentrations of theophylline, warfarin, and propranolol, as zileuton can increase serum concentrations of these medications when taken simultaneously. [13] Monitor for neuropsychiatric adverse drug reactions such as sleep disorders and behavior changes. Monitor pulmonary function tests (typically reversible obstructive pattern) in patients with asthma. [32] National Institute for Clinical Excellence guidelines\u00a0suggest\u00a0spirometry for monitoring asthma at each\u00a0clinic visit or at least after 3 or 6 months from the commencement of\u00a0treatment and afterward every 1 to 2 years. [32] Monitor estimated peak expiratory flow rate; measurements can be variable according to age, height, and race. [33] [34] Repeated peak flow measurement is simple to execute in clinical settings. [35]"}
{"id": "article-31467_25", "title": "Zileuton -- Toxicity", "content": "Overdose is treated based on symptoms with supportive care if a patient has signs of toxicity. Dialysis does not remove zileuton from the bloodstream. Treatment with gastric lavage may be necessary to eliminate any unabsorbed drug. Limited guidelines exist around the approach to overdose. According to product labeling, a case report of a patient taking between 6.6 and 9.0 g of zileuton and completely recovering without complications is reported. The clinician should consult a medical toxicologist or poison control center for up-to-date information on the management of zileuton overdose.\u00a0The American Association of Poison Control Centers and National Poison Data System research reinforces the importance of expertise and the need for specialized medical toxicology knowledge to manage drug overdose. [36]", "contents": "Zileuton -- Toxicity. Overdose is treated based on symptoms with supportive care if a patient has signs of toxicity. Dialysis does not remove zileuton from the bloodstream. Treatment with gastric lavage may be necessary to eliminate any unabsorbed drug. Limited guidelines exist around the approach to overdose. According to product labeling, a case report of a patient taking between 6.6 and 9.0 g of zileuton and completely recovering without complications is reported. The clinician should consult a medical toxicologist or poison control center for up-to-date information on the management of zileuton overdose.\u00a0The American Association of Poison Control Centers and National Poison Data System research reinforces the importance of expertise and the need for specialized medical toxicology knowledge to manage drug overdose. [36]"}
{"id": "article-31467_26", "title": "Zileuton -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional healthcare team, including the primary care clinicians, physician assistants, and nurse practitioners who prescribe zileuton, should be familiar with the drug's indications and contraindications. Zileuton is only used for prophylaxis of asthma and is not recommended for monotherapy. It also has several off-label uses. Clinicians should monitor the patient's liver function on zileuton regularly.\u00a0Nurses can monitor for\u00a0any\u00a0neuropsychiatric symptoms and report to the clinician team.  According to the CDC, moderate to severe asthma is a risk factor for severe COVID-19 infection. [37] Pharmacists can ensure the drug is dosed appropriately, check for interactions, and counsel patients on the proper use and administration of the medication.", "contents": "Zileuton -- Enhancing Healthcare Team Outcomes. The interprofessional healthcare team, including the primary care clinicians, physician assistants, and nurse practitioners who prescribe zileuton, should be familiar with the drug's indications and contraindications. Zileuton is only used for prophylaxis of asthma and is not recommended for monotherapy. It also has several off-label uses. Clinicians should monitor the patient's liver function on zileuton regularly.\u00a0Nurses can monitor for\u00a0any\u00a0neuropsychiatric symptoms and report to the clinician team.  According to the CDC, moderate to severe asthma is a risk factor for severe COVID-19 infection. [37] Pharmacists can ensure the drug is dosed appropriately, check for interactions, and counsel patients on the proper use and administration of the medication."}
{"id": "article-31467_27", "title": "Zileuton -- Enhancing Healthcare Team Outcomes", "content": "A pulmonologist or immunologist consultation may be required if asthma is uncontrolled despite optimal medical therapy. The Asthma Quality of Life Questionnaire can assess quality of life. [38] Zileuton\u00a0can interact with drugs like Warfarin, Theophylline, and Propranolol; therefore, a pharmacist should thoroughly review the patient's medication profile to prevent drug interactions. In an overdose of zileuton, a medical toxicologist and intensivist consultation are necessary. A psychiatrist consultation is also required if the overdose is intentional. All healthcare professionals, including clinicians, immunologists or pulmonologists, pharmacists, medical toxicologists, and nurses, should use interprofessional team strategies to improve care coordination and patient outcomes when using zileuton\u00a0for asthma.", "contents": "Zileuton -- Enhancing Healthcare Team Outcomes. A pulmonologist or immunologist consultation may be required if asthma is uncontrolled despite optimal medical therapy. The Asthma Quality of Life Questionnaire can assess quality of life. [38] Zileuton\u00a0can interact with drugs like Warfarin, Theophylline, and Propranolol; therefore, a pharmacist should thoroughly review the patient's medication profile to prevent drug interactions. In an overdose of zileuton, a medical toxicologist and intensivist consultation are necessary. A psychiatrist consultation is also required if the overdose is intentional. All healthcare professionals, including clinicians, immunologists or pulmonologists, pharmacists, medical toxicologists, and nurses, should use interprofessional team strategies to improve care coordination and patient outcomes when using zileuton\u00a0for asthma."}
{"id": "article-31467_28", "title": "Zileuton -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Zileuton -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}